Skip to content

    Recently Viewed


      lede-A Message from Chairman and CEO Alex Gorsky About Johnson & Johnson's Investigational COVID-19 Vaccine Candidate.jpg

      A message from Chairman and CEO Alex Gorsky about Johnson & Johnson’s investigational COVID-19 vaccine candidate

      The company leader shares the latest news about topline results from the Phase 3 clinical trial for its single-dose investigational COVID-19 vaccine candidate.

      Share Article
      share to

      One year ago this week, Johnson & Johnson pledged that we would leverage all of our capabilities to fight an emerging threat, then being referred to as simply “the novel coronavirus.” Since then, we have focused our efforts on delivering a single-dose vaccine that would be a safe, effective and efficient solution for the largest number of people around the world.

      I couldn’t be more proud—or grateful—to share that we have made a significant step towards reaching our ambitious goal.

      Today, we shared positive topline Phase 3 clinical trial results for our single-dose investigational COVID-19 vaccine candidate. We will continue to work with health authorities around the world on regulatory applications.

      Johnson & Johnson was built for times like these—and from day one, we have kept science, transparency and collaboration at the center of all our efforts to fight this deadly pandemic.

      COVID-19 has touched the lives of every person on this planet and tested us as a society and as individuals. But Johnson & Johnson was built for times like these—and from day one, we have kept science, transparency and collaboration at the center of all our efforts to fight this deadly pandemic. Our work on an investigational COVID-19 vaccine will be an enduring point of pride for us for decades to come.

      Doing our part to combat the greatest public health crisis in living memory has been a huge undertaking for our company. I owe a deep debt of gratitude to the incredible teams that made this milestone a reality, and to each and every one of my 135,000 colleagues for living into Our Credo values with great resilience and agility to ensure we keep meeting the healthcare needs of all who rely on Johnson & Johnson.

      COVID-19 continues to inflict heartbreak and hardship, and there is still much that must be done to bring this pandemic to an end. But I am more optimistic than ever that these dark days are numbered.

      I hope that our announcement today serves as a welcome reminder of the transformative power of science, the multiplying effect of collaboration and—most of all—the possibility of a better, healthier future.

      Stay Up to Date on Johnson & Johnson’s Janssen COVID-19 Vaccine

      See answers to frequently asked questions, learn about the company’s innovative vaccine technology platform and more.
      A close-up view of the novel coronavirus

      More from Johnson & Johnson

      Blue latex-gloved hands holding a beaker filled with yellow liquid

      IBD rates are rising in communities of color. Can these innovators help?

      Scientists aren’t sure what’s behind the upward trend. That’s why Johnson & Johnson Innovation put out the call to address this troubling health disparity.
      DNA illustration genetic material

      Harnessing the human genome is the future of healthcare—and Johnson & Johnson is helping lead the way

      The company’s partnership with the largest human genome sequencing project in the world will increase scientists’ understanding of genetic diseases and help create new interventions. Here, a look at the breakthroughs that have guided the understanding of the power of DNA.
      Health & wellness
      1123 BTN-Lung Cancer-Iede2.jpg
      Health & wellness

      By the numbers: Who gets lung cancer?

      Each year, more people die of lung cancer than colon, breast and prostate cancers combined. Learn how Johnson & Johnson is dedicated to improving outcomes by integrating the company’s MedTech and Innovative Medicine expertise.
      You are now leaving and going to a site with a different privacy policy. Please click below to continue to that site.